VISTAGEN THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
VISTAGEN THERAPEUTICS INC. - More news...
VISTAGEN THERAPEUTICS INC. - More news...
- Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
- Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
- Vistagen to Acquire Pherin Pharmaceuticals
- Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
- Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
- Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
- Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
- Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
- Vistagen to Present at Stifel 2022 Healthcare Conference
- Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
- Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
- Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
- Vistagen to Participate at Cantor Neurology & Psychiatry Conference
- Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
- Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
- Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
- Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
- VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
- VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
- Thinking about buying stock in Exela Technologies, Redbox Entertainment, Vistagen Therapeutics, Toughbuilt Industries, or Infrastructure & Energy Alternatives?
- Thinking about buying stock in Snap, Vistagen Therapeutics, Blue Hat, Rivian Automotive, or AT&T?
- VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
- VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
- VistaGen to Participate at William Blair Biotech Focus Conference 2022
- VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
- VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
- VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
- VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
- VistaGen to Participate in Upcoming June Investor Conferences
- VistaGen Appoints Reid Adler as Chief Legal Officer